Urine concentrating defect in prostaglandin EP1-deficient mice

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 2, 2007, Pages

  Kennedy, Chris R J ^a,b,d   Xiong, Huaqi ^a   Rahal, Sherine ^a,b   Vanderluit, Jacqueline ^a   Slack, Ruth S ^a   Zhang, Yahua ^c   Guan, Youfei ^c   Breyer, Matthew D ^c   Hébert, Richard L ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

EP1 receptor; Prostaglandin E2; Urine concentration; Vasopressin

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ANTIDIURESIS; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; HORMONE INHIBITION; IMMUNOHISTOCHEMISTRY; KIDNEY COLLECTING TUBULE; KIDNEY CONCENTRATING CAPACITY; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; MOUSE; NONHUMAN; PLASMA OSMOLALITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPRAOPTIC NUCLEUS; URINE OSMOLALITY; WATER DEPRIVATION; WATER LOADING; WILD TYPE;

EID: 33846872813     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00183.2005     Document Type: Article

References (35)

1. Anderson RJ, Berl T, McDonald KD, and Schrier RW. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest 56: 420-426, 1975.
2. Antunes-Rodrigues J, de Castro M, Elias LL, Valenca MM, and McCann SM. Neuroendocrine control of body fluid metabolism. Physiol Rev 84: 169-208, 2004.
3. Arima H, Kondo K, Kakiya S, Nagasaki H, Yokoi H, Yambe Y, Murase T, Iwasaki Y, and Oiso Y. Rapid and sensitive vasopressin heteronuclear RNA responses to changes in plasma osmolality. J Neuroendocrinol 11: 337-341, 1999.
4. Batshake B, Nilsson C, and Sundelin J. Molecular characterization of the mouse prostanoid EP1 receptor gene. Eur J Biochem 231: 809-814, 1995.
5. Berl T, Raz A, Wald H, Horowitz J, and Czaczkes W. Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat. Am J Physiol Renal Fluid Electrolyte Physiol 232: F529-F537, 1977.
6. Breyer RM, Bagdassarian CK, Myers SA, and Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690, 2001.
7. Brooks DP, Share L, and Crofton JT. Role of brain prostaglandins in the control of vasopressin secretion in the conscious rat. Endocrinology 118: 1716-1722, 1986.
8. Coleman RA, Grix SP, Head SA, Loutit JB, Mallett A, and Sheldrick RLG. A novel inhibitory receptor in piglet saphenous vein. Prostaglandins 47: 151-168, 1994.
9. Coleman RA, Kennedy I, Humphrey PPA, Bunce K, and Lumley P. Prostanoids and their receptors. In: Comprehensive Medical Chemistry, edited by Emmet JC. Oxford: Pergammon Press, 1990, p. 643-714.
10. Coleman RA, Smith WL, and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229, 1994.
11. Fenton RA, Chou CL, Stewart GS, Smith CP, and Knepper MA. Urinary concentrating defect in mice with selective deletion of phloretinsensitive urea transporters in the renal collecting duct. Proc Natl Acad Sci USA 101: 7469-7474, 2004.
12. 2. Am J Physiol Renal Physiol 275: F955-F961, 1998.
13. Hashimoto H, Noto T, and Nakajima T. A study on the release mechanism of vasopressin and oxytocin. Neuropeptides 12: 199-206, 1988.
14. 2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol Renal Fluid Electrolyte Physiol 259: F318-F325, 1990.
15. Hebert RL, Jacobson HR, and Breyer MD. Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest 87: 1992-1998, 1991.
16. 2 receptors modulate water and sodium transport in rabbit cortical collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 265: F643-F650, 1993.
17. Hull MA, Ko SC, and Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 3: 1031-1039, 2004.
18. Ishikawa S, Saito T, and Yoshida S. The effect of prostaglandins on the release of arginine vasopressin from the guinea pig hypothalamo- neurohypophyseal complex in organ culture. Endocrinology 108: 193-198, 1981.
19. Jensen BL, Mann B, Skott O, and Kurtz A. Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat. Kidney Int 56: 528-537, 1999.
20. Kawamori T, Kitamura T, Watanabe K, Uchiya N, Maruyama T, Narumiya S, Sugimura T, and Wakabayashi K. Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis 26: 353-357, 2005.
21. Kim SW, Kim JW, Choi KC, Ma SK, Oh Y, Jung JY, Kim J, and Lee J. Indomethacin enhances shuttling of aquaporin-2 despite decreased abundance in rat kidney. J Am Soc Nephrol 15: 2998-3005, 2004.
22. Knigge U, Kjaer A, Kristoffersen U, Madsen K, Toftegaard C, Jorgensen H, and Warberg J. Histamine and prostaglandin interaction in regulation of oxytocin and vasopressin secretion. J Neuroendocrinol 15: 940-945, 2003.
23. Makino H, Tanaka I, Mukoyama M, Sugawara A, Mori K, Muro S, Suganami T, Yahata K, Ishibashi R, Ohuchida S, Maruyama T, Narumiya S, and Nakao K. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 13: 1757-1765, 2002.
24. Matsuoka Y, Furuyashiki T, Bito H, Ushikubi F, Tanaka Y, Kobayashi T, Muro S, Satoh N, Kayahara T, Higashi M, Mizoguchi A, Shichi H, Fukuda Y, Nakao K, and Narumiya S. Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypes. Proc Natl Acad Sci USA 100: 4132-4137, 2003.
25. Murillo-Carretero MI, Ilundain AA, and Echevarria M. Regulation of aquaporin mRNA expression in rat kidney by water intake. J Am Soc Nephrol 10: 696-703, 1999.
26. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, and Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82: 205-244, 2002.
27. 2 regulates cAMP production in cultured rabbit CCD cells: evidence for dual inhibitory mechanisms. Am J Physiol Cell Physiol 263: C1208-C1215, 1992.
28. Puurunen J and Leppaluoto J. Centrally administered PGE2 inhibits gastric secretion in the rat by releasing vasopressin. Eur J Pharmacol 104: 145-150, 1984.
29. Sakairi Y, Jacobson HR, Noland TD, and Breyer MD. Luminal prostaglandin E receptors regulate salt and water transport in rabbit cortical collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 269: F257-F265, 1995.
30. Schmidt-Nielsen B, Graves B, and Roth J. Water removal and solute additions determining increases in renal medullary osmolality. Am J Physiol Renal Physiol 244: F472-F482, 1983.
31. Stock JL, Shinjo K, Burkhardt J, Roach M, Taniguchi K, Ishikawa T, Kim HS, Flannery PJ, Coffman TM, McNeish JD, and Audoly LP. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 107: 325-331, 2001.
32. Suganami T, Mori K, Tanaka I, Mukoyama M, Sugawara A, Makino H, Muro S, Yahata K, Ohuchida S, Maruyama T, Narumiya S, and Nakao K. Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 42: 1183-1190, 2003.
33. Tamma G, Wiesner B, Furkert J, Hahm D, Oksche A, Schaefer M, Valenti G, Rosenthal W, and Klussmann E. The prostaglandin E2 analog sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho. J Cell Sci 116: 3285-3294, 2003.
34. Vilhardt H and Hedqvist P. A possible role of prostaglandin E2 in the regulation of vasopressin secretion in rats. Life Sci 9: 825-830, 1970.
35. 2 interaction with AVP: effects on AQP2 phosphorylation and distribution. Am J Physiol Renal Physiol 278: F388-F394, 2000.